IGHE and prostate cancer: The synthesized human tumor-specific IgE’s such as MOv18 IgE for ovarian carcinoma (47), Trastuzumab and C6MH3-B1 IgE’s for breast (50), colon (58), and ovarian (47) cancers, Cetuximab IgE for breast and epidermoid carcinoma (52), anti-hCD20 for human B-cell lymphoma (53), anti-PSA for human prostate cancer (55), have been investigated by many research groups (Tables 2 and 3).